Shares in the Spanish pharmaceutical company Almirall jumped 10% on the Madrid stock exchange on Monday after reporting a "solid start to the year" for FY 2025.
The Barcelona-based group reported a 15% y-o-y increase in revenue, including a 23.4% rise in its dermatology business in Europe, its growth driver.
At €284.6m, its net revenue exceeded the consensus estimate of €282.6m, thanks to the strength of its dermatology franchises, including its psoriasis treatment Ilumetri (+12.7%) and its atypical dermatitis drug Ebglyss (+50%).
Operating profit rose 35% to €70.9m, again exceeding the consensus forecast of €68.6m.
Believing that these results are in line with its objective of sustained growth, Almirall confirmed its target of 10% to 13% revenue growth for 2025, with EBITDA expected to between €220m and €240m.
On the Madrid Stock Exchange, the share price rose 10% following this announcement.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
Almirall SA is a Spain-based company principally engaged in the pharmaceuticals manufacture. The Company focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating agents. The Company's activities are divided into four business segments: Own network, which focuses on the commercialization of pharmaceuticals through own brand names; Licenses, which sells product rights to third parties; Research and development (R&D), which is responsible for the creation of drug candidates, as well as Dermatology, which includes sale of dermatological medicines in the United States. The Company operates through numerous subsidiaries in Europe, the Americas, Africa, Asia and Australia.
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
